» Articles » PMID: 15539465

Effects of Processing and Storage Conditions on Amyloid Beta (1-42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice

Overview
Journal Clin Chem
Specialty Biochemistry
Date 2004 Nov 13
PMID 15539465
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Reported concentrations of amyloid beta (1-42) (A beta 42) and tau in cerebrospinal fluid (CSF) differ among reports. We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of A beta 42 and tau in CSF.

Methods: Stability of samples stored at -80 degrees C was determined by use of an accelerated stability testing protocol according to the Arrhenius equation. A beta 42 and tau concentrations were measured in CSF samples stored at 4, 18, 37, and -80 degrees C. Relative CSF concentrations (%) of the biomarkers after one freeze/thaw cycle were compared with those after two, three, four, five, and six freeze/thaw cycles. In addition, relative A beta 42 and tau concentrations in samples not centrifuged were compared with samples centrifuged after 1, 4, 48, and 72 h.

Results: A beta 42 and tau concentrations were stable in CSF when stored for a long period at -80 degrees C. CSF A beta 42 decreased by 20% during the first 2 days at 4, 18, and 37 degrees C compared with -80 degrees C. CSF tau decreased after storage for 12 days at 37 degrees C. After three freeze/thaw cycles, CSF A beta 42 decreased 20%. CSF tau was stable during six freeze/thaw cycles. Centrifugation did not influence the biomarker concentrations.

Conclusions: Repeated freeze/thaw cycles and storage at 4, 18, and 37 degrees C influence the quantitative result of the A beta 42 test. Preferably, samples should be stored at -80 degrees C immediately after collection.

Citing Articles

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.


Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study.

Pils M, Dybala A, Schaffrath A, Rehn F, Kutzsche J, Blomeke L Alzheimers Res Ther. 2024; 16(1):223.

PMID: 39402637 PMC: 11472473. DOI: 10.1186/s13195-024-01597-3.


Neuro-Urology and Biobanking: An Integrated Approach for Advancing Research and Improving Patient Care.

Botter S, Kessler T Int J Mol Sci. 2023; 24(18).

PMID: 37762582 PMC: 10531693. DOI: 10.3390/ijms241814281.


Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias.

Hu W, Nayyar A, Kaluzova M Neurotherapeutics. 2023; 20(4):955-974.

PMID: 37378862 PMC: 10457281. DOI: 10.1007/s13311-023-01370-8.


Development and Implementation of an Internal Quality Control Sample to Standardize Oligomer-Based Diagnostics of Alzheimer's Disease.

Pils M, Dybala A, Rehn F, Blomeke L, Bujnicki T, Kraemer-Schulien V Diagnostics (Basel). 2023; 13(10).

PMID: 37238187 PMC: 10217173. DOI: 10.3390/diagnostics13101702.